nodes	percent_of_prediction	percent_of_DWPC	metapath
Levonorgestrel—AR—scrotum—sarcoma	0.0385	0.169	CbGeAlD
Levonorgestrel—CYP3A4—Thiotepa—sarcoma	0.0321	0.458	CbGbCtD
Levonorgestrel—SHBG—hindlimb—sarcoma	0.0183	0.0804	CbGeAlD
Levonorgestrel—ESR1—periosteum—sarcoma	0.0181	0.0796	CbGeAlD
Levonorgestrel—CYP3A4—Mitoxantrone—sarcoma	0.0138	0.197	CbGbCtD
Levonorgestrel—CYP3A4—Vincristine—sarcoma	0.0095	0.136	CbGbCtD
Levonorgestrel—CYP3A4—Etoposide—sarcoma	0.00871	0.124	CbGbCtD
Levonorgestrel—SRD5A1—testis—sarcoma	0.00699	0.0308	CbGeAlD
Levonorgestrel—PGR—mammary gland—sarcoma	0.00687	0.0302	CbGeAlD
Levonorgestrel—SRD5A1—liver—sarcoma	0.00661	0.0291	CbGeAlD
Levonorgestrel—CYP3A4—Doxorubicin—sarcoma	0.00594	0.0847	CbGbCtD
Levonorgestrel—ESR1—mammary gland—sarcoma	0.00537	0.0236	CbGeAlD
Levonorgestrel—PGR—myometrium—sarcoma	0.00488	0.0215	CbGeAlD
Levonorgestrel—SHBG—hematopoietic system—sarcoma	0.00465	0.0204	CbGeAlD
Levonorgestrel—SHBG—connective tissue—sarcoma	0.00447	0.0197	CbGeAlD
Levonorgestrel—PGR—hematopoietic system—sarcoma	0.00419	0.0184	CbGeAlD
Levonorgestrel—PGR—connective tissue—sarcoma	0.00403	0.0177	CbGeAlD
Levonorgestrel—AR—myometrium—sarcoma	0.00388	0.0171	CbGeAlD
Levonorgestrel—ESR1—myometrium—sarcoma	0.00381	0.0168	CbGeAlD
Levonorgestrel—CYP19A1—hematopoietic system—sarcoma	0.00377	0.0166	CbGeAlD
Levonorgestrel—PGR—smooth muscle tissue—sarcoma	0.00369	0.0162	CbGeAlD
Levonorgestrel—ESR1—embryo—sarcoma	0.00367	0.0161	CbGeAlD
Levonorgestrel—CYP19A1—connective tissue—sarcoma	0.00363	0.016	CbGeAlD
Levonorgestrel—SHBG—uterus—sarcoma	0.00351	0.0154	CbGeAlD
Levonorgestrel—AR—seminal vesicle—sarcoma	0.00351	0.0154	CbGeAlD
Levonorgestrel—AR—hematopoietic system—sarcoma	0.00334	0.0147	CbGeAlD
Levonorgestrel—ESR1—hematopoietic system—sarcoma	0.00327	0.0144	CbGeAlD
Levonorgestrel—AR—connective tissue—sarcoma	0.00321	0.0141	CbGeAlD
Levonorgestrel—PGR—uterus—sarcoma	0.00316	0.0139	CbGeAlD
Levonorgestrel—ESR1—connective tissue—sarcoma	0.00315	0.0139	CbGeAlD
Levonorgestrel—SHBG—bone marrow—sarcoma	0.00298	0.0131	CbGeAlD
Levonorgestrel—PGR—lymphoid tissue—sarcoma	0.00295	0.013	CbGeAlD
Levonorgestrel—AR—smooth muscle tissue—sarcoma	0.00294	0.0129	CbGeAlD
Levonorgestrel—AR—skin of body—sarcoma	0.0029	0.0128	CbGeAlD
Levonorgestrel—ESR1—smooth muscle tissue—sarcoma	0.00288	0.0127	CbGeAlD
Levonorgestrel—CYP19A1—uterus—sarcoma	0.00285	0.0125	CbGeAlD
Levonorgestrel—SHBG—testis—sarcoma	0.00255	0.0112	CbGeAlD
Levonorgestrel—AR—cardiac atrium—sarcoma	0.00253	0.0111	CbGeAlD
Levonorgestrel—AR—uterus—sarcoma	0.00252	0.0111	CbGeAlD
Levonorgestrel—ESR1—uterus—sarcoma	0.00247	0.0109	CbGeAlD
Levonorgestrel—SHBG—liver—sarcoma	0.00241	0.0106	CbGeAlD
Levonorgestrel—AR—lymphoid tissue—sarcoma	0.00235	0.0103	CbGeAlD
Levonorgestrel—ESR1—lymphoid tissue—sarcoma	0.00231	0.0101	CbGeAlD
Levonorgestrel—PGR—testis—sarcoma	0.00229	0.0101	CbGeAlD
Levonorgestrel—AR—tendon—sarcoma	0.00221	0.00971	CbGeAlD
Levonorgestrel—CYP19A1—testis—sarcoma	0.00206	0.00908	CbGeAlD
Levonorgestrel—ESR1—Estrogen Receptor Pathway—JUN—sarcoma	0.00206	0.00991	CbGpPWpGaD
Levonorgestrel—CYP19A1—liver—sarcoma	0.00195	0.00859	CbGeAlD
Levonorgestrel—ESR1—Regulation of Telomerase—WT1—sarcoma	0.00194	0.00936	CbGpPWpGaD
Levonorgestrel—AR—Nongenotropic Androgen signaling—CREB1—sarcoma	0.00185	0.00892	CbGpPWpGaD
Levonorgestrel—AR—testis—sarcoma	0.00183	0.00804	CbGeAlD
Levonorgestrel—CYP3A4—hematopoietic system—sarcoma	0.00183	0.00804	CbGeAlD
Levonorgestrel—ESR1—Regulation of nuclear SMAD2/3 signaling—MYOD1—sarcoma	0.00182	0.00876	CbGpPWpGaD
Levonorgestrel—ESR1—Estrogen signaling pathway—CREB1—sarcoma	0.00181	0.00873	CbGpPWpGaD
Levonorgestrel—ESR1—testis—sarcoma	0.00179	0.00789	CbGeAlD
Levonorgestrel—CYP19A1—FSH signaling pathway—CREB1—sarcoma	0.00178	0.00858	CbGpPWpGaD
Levonorgestrel—AR—liver—sarcoma	0.00173	0.0076	CbGeAlD
Levonorgestrel—ESR1—liver—sarcoma	0.0017	0.00746	CbGeAlD
Levonorgestrel—AR—Regulation of Androgen receptor activity—FOXO1—sarcoma	0.00166	0.00801	CbGpPWpGaD
Levonorgestrel—PGR—lymph node—sarcoma	0.00166	0.00732	CbGeAlD
Levonorgestrel—ESR1—Plasma membrane estrogen receptor signaling—IGF1R—sarcoma	0.00165	0.00796	CbGpPWpGaD
Levonorgestrel—AR—Notch-mediated HES/HEY network—KDR—sarcoma	0.00151	0.0073	CbGpPWpGaD
Levonorgestrel—CYP19A1—lymph node—sarcoma	0.0015	0.00658	CbGeAlD
Levonorgestrel—ESR1—Leptin signaling pathway—PLCG1—sarcoma	0.00137	0.00659	CbGpPWpGaD
Levonorgestrel—AR—lymph node—sarcoma	0.00132	0.00583	CbGeAlD
Levonorgestrel—ESR1—Estrogen signaling pathway—JUN—sarcoma	0.0013	0.00628	CbGpPWpGaD
Levonorgestrel—ESR1—lymph node—sarcoma	0.0013	0.00572	CbGeAlD
Levonorgestrel—ESR1—Signaling mediated by p38-alpha and p38-beta—CREB1—sarcoma	0.0013	0.00624	CbGpPWpGaD
Levonorgestrel—AR—Nongenotropic Androgen signaling—SRC—sarcoma	0.0012	0.00576	CbGpPWpGaD
Levonorgestrel—AR—Regulation of nuclear SMAD2/3 signaling—FOXO1—sarcoma	0.00118	0.00571	CbGpPWpGaD
Levonorgestrel—ESR1—ATF-2 transcription factor network—PDGFRA—sarcoma	0.00116	0.00557	CbGpPWpGaD
Levonorgestrel—CYP19A1—FSH signaling pathway—SRC—sarcoma	0.00115	0.00553	CbGpPWpGaD
Levonorgestrel—AR—Integrated Pancreatic Cancer Pathway—WT1—sarcoma	0.0011	0.00532	CbGpPWpGaD
Levonorgestrel—AR—Androgen receptor signaling pathway—FOXO1—sarcoma	0.0011	0.00529	CbGpPWpGaD
Levonorgestrel—ESR1—LKB1 signaling events—CREB1—sarcoma	0.0011	0.00529	CbGpPWpGaD
Levonorgestrel—ESR1—Plasma membrane estrogen receptor signaling—MMP2—sarcoma	0.00106	0.00512	CbGpPWpGaD
Levonorgestrel—ESR1—FOXM1 transcription factor network—MMP2—sarcoma	0.00104	0.00502	CbGpPWpGaD
Levonorgestrel—AR—FOXA1 transcription factor network—JUN—sarcoma	0.00101	0.00485	CbGpPWpGaD
Levonorgestrel—AR—Regulation of Androgen receptor activity—MDM2—sarcoma	0.000998	0.00481	CbGpPWpGaD
Levonorgestrel—PGR—Validated nuclear estrogen receptor alpha network—CCND1—sarcoma	0.000981	0.00473	CbGpPWpGaD
Levonorgestrel—PGR—Validated nuclear estrogen receptor alpha network—JUN—sarcoma	0.000979	0.00472	CbGpPWpGaD
Levonorgestrel—ESR1—Leptin signaling pathway—FOXO1—sarcoma	0.00097	0.00467	CbGpPWpGaD
Levonorgestrel—AR—Integrated Breast Cancer Pathway—ATF1—sarcoma	0.000964	0.00464	CbGpPWpGaD
Levonorgestrel—CYP19A1—Tryptophan metabolism—MDM2—sarcoma	0.000962	0.00463	CbGpPWpGaD
Levonorgestrel—CYP3A4—liver—sarcoma	0.000946	0.00416	CbGeAlD
Levonorgestrel—PGR—Signaling by ERBB4—FOXO1—sarcoma	0.00094	0.00453	CbGpPWpGaD
Levonorgestrel—PGR—Signaling by ERBB4—PDGFRB—sarcoma	0.000938	0.00452	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling mediated by p38-alpha and p38-beta—JUN—sarcoma	0.000931	0.00449	CbGpPWpGaD
Levonorgestrel—PGR—Signaling by ERBB4—PDGFRA—sarcoma	0.000923	0.00445	CbGpPWpGaD
Levonorgestrel—ESR1—Regulation of nuclear SMAD2/3 signaling—FOXO1—sarcoma	0.000913	0.0044	CbGpPWpGaD
Levonorgestrel—AR—Regulation of Androgen receptor activity—JUN—sarcoma	0.000868	0.00418	CbGpPWpGaD
Levonorgestrel—AR—Regulation of nuclear SMAD2/3 signaling—CREB1—sarcoma	0.000859	0.00414	CbGpPWpGaD
Levonorgestrel—ESR1—ATF-2 transcription factor network—CREB1—sarcoma	0.000853	0.00411	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—WT1—sarcoma	0.000851	0.0041	CbGpPWpGaD
Levonorgestrel—AR—Nongenotropic Androgen signaling—HRAS—sarcoma	0.000841	0.00405	CbGpPWpGaD
Levonorgestrel—CYP19A1—Integrated Breast Cancer Pathway—ATF1—sarcoma	0.000829	0.00399	CbGpPWpGaD
Levonorgestrel—AR—Regulation of nuclear beta catenin signaling and target gene transcription—MMP2—sarcoma	0.000808	0.00389	CbGpPWpGaD
Levonorgestrel—ESR1—FOXM1 transcription factor network—CCND1—sarcoma	0.000807	0.00389	CbGpPWpGaD
Levonorgestrel—AR—Androgen receptor signaling pathway—CREB1—sarcoma	0.000797	0.00384	CbGpPWpGaD
Levonorgestrel—ESR1—ATF-2 transcription factor network—MMP2—sarcoma	0.000794	0.00382	CbGpPWpGaD
Levonorgestrel—PGR—Validated nuclear estrogen receptor alpha network—MYC—sarcoma	0.000787	0.00379	CbGpPWpGaD
Levonorgestrel—AR—Regulation of Androgen receptor activity—SRC—sarcoma	0.000778	0.00375	CbGpPWpGaD
Levonorgestrel—AR—Coregulation of Androgen receptor activity—CCND1—sarcoma	0.000777	0.00374	CbGpPWpGaD
Levonorgestrel—Cough—Etoposide—sarcoma	0.000776	0.00157	CcSEcCtD
Levonorgestrel—ESR1—FOXA1 transcription factor network—JUN—sarcoma	0.000776	0.00374	CbGpPWpGaD
Levonorgestrel—Somnolence—Mitoxantrone—sarcoma	0.000775	0.00157	CcSEcCtD
Levonorgestrel—Gastrointestinal disorder—Vincristine—sarcoma	0.000773	0.00156	CcSEcCtD
Levonorgestrel—Fatigue—Vincristine—sarcoma	0.000772	0.00156	CcSEcCtD
Levonorgestrel—AR—Coregulation of Androgen receptor activity—CTNNB1—sarcoma	0.000769	0.00371	CbGpPWpGaD
Levonorgestrel—Dyspepsia—Mitoxantrone—sarcoma	0.000768	0.00155	CcSEcCtD
Levonorgestrel—Hypertension—Etoposide—sarcoma	0.000768	0.00155	CcSEcCtD
Levonorgestrel—Pain—Vincristine—sarcoma	0.000766	0.00155	CcSEcCtD
Levonorgestrel—Constipation—Vincristine—sarcoma	0.000766	0.00155	CcSEcCtD
Levonorgestrel—Pain in extremity—Doxorubicin—sarcoma	0.000766	0.00155	CcSEcCtD
Levonorgestrel—Dry skin—Epirubicin—sarcoma	0.000758	0.00153	CcSEcCtD
Levonorgestrel—Decreased appetite—Mitoxantrone—sarcoma	0.000758	0.00153	CcSEcCtD
Levonorgestrel—Chest pain—Etoposide—sarcoma	0.000757	0.00153	CcSEcCtD
Levonorgestrel—Migraine—Doxorubicin—sarcoma	0.000754	0.00152	CcSEcCtD
Levonorgestrel—Affect lability—Doxorubicin—sarcoma	0.000754	0.00152	CcSEcCtD
Levonorgestrel—Fatigue—Mitoxantrone—sarcoma	0.000752	0.00152	CcSEcCtD
Levonorgestrel—Unspecified disorder of skin and subcutaneous tissue—Etoposide—sarcoma	0.000752	0.00152	CcSEcCtD
Levonorgestrel—Discomfort—Etoposide—sarcoma	0.000748	0.00151	CcSEcCtD
Levonorgestrel—Breast disorder—Epirubicin—sarcoma	0.000748	0.00151	CcSEcCtD
Levonorgestrel—Pain—Mitoxantrone—sarcoma	0.000746	0.00151	CcSEcCtD
Levonorgestrel—Constipation—Mitoxantrone—sarcoma	0.000746	0.00151	CcSEcCtD
Levonorgestrel—Hypersensitivity—Thiotepa—sarcoma	0.000744	0.0015	CcSEcCtD
Levonorgestrel—ESR1—AP-1 transcription factor network—CREB1—sarcoma	0.000744	0.00358	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Breast Cancer Pathway—ATF1—sarcoma	0.000742	0.00358	CbGpPWpGaD
Levonorgestrel—Hypersensitivity—Dactinomycin—sarcoma	0.000739	0.00149	CcSEcCtD
Levonorgestrel—ESR1—Plasma membrane estrogen receptor signaling—SRC—sarcoma	0.000736	0.00355	CbGpPWpGaD
Levonorgestrel—Gastrointestinal pain—Vincristine—sarcoma	0.000732	0.00148	CcSEcCtD
Levonorgestrel—SRD5A1—Metabolism—ENO2—sarcoma	0.00073	0.00352	CbGpPWpGaD
Levonorgestrel—SRD5A1—Metabolism—HBA1—sarcoma	0.000725	0.00349	CbGpPWpGaD
Levonorgestrel—Mood swings—Doxorubicin—sarcoma	0.000725	0.00147	CcSEcCtD
Levonorgestrel—Asthenia—Thiotepa—sarcoma	0.000725	0.00146	CcSEcCtD
Levonorgestrel—Infection—Etoposide—sarcoma	0.000721	0.00146	CcSEcCtD
Levonorgestrel—Abdominal distension—Epirubicin—sarcoma	0.00072	0.00145	CcSEcCtD
Levonorgestrel—AR—Integrated Breast Cancer Pathway—FOXO1—sarcoma	0.00072	0.00347	CbGpPWpGaD
Levonorgestrel—Asthenia—Dactinomycin—sarcoma	0.000719	0.00145	CcSEcCtD
Levonorgestrel—PGR—Signaling by ERBB4—KIT—sarcoma	0.000716	0.00345	CbGpPWpGaD
Levonorgestrel—Asthma—Epirubicin—sarcoma	0.000715	0.00144	CcSEcCtD
Levonorgestrel—Influenza—Epirubicin—sarcoma	0.000715	0.00144	CcSEcCtD
Levonorgestrel—Pruritus—Thiotepa—sarcoma	0.000715	0.00144	CcSEcCtD
Levonorgestrel—Gastrointestinal pain—Mitoxantrone—sarcoma	0.000713	0.00144	CcSEcCtD
Levonorgestrel—ESR1—Plasma membrane estrogen receptor signaling—NRAS—sarcoma	0.000708	0.00341	CbGpPWpGaD
Levonorgestrel—Body temperature increased—Vincristine—sarcoma	0.000708	0.00143	CcSEcCtD
Levonorgestrel—Abdominal pain—Vincristine—sarcoma	0.000708	0.00143	CcSEcCtD
Levonorgestrel—Skin disorder—Etoposide—sarcoma	0.000705	0.00142	CcSEcCtD
Levonorgestrel—ESR1—Leptin signaling pathway—CREB1—sarcoma	0.000704	0.00339	CbGpPWpGaD
Levonorgestrel—Dry skin—Doxorubicin—sarcoma	0.000702	0.00142	CcSEcCtD
Levonorgestrel—Hyperhidrosis—Etoposide—sarcoma	0.000701	0.00142	CcSEcCtD
Levonorgestrel—Urticaria—Mitoxantrone—sarcoma	0.000693	0.0014	CcSEcCtD
Levonorgestrel—Breast disorder—Doxorubicin—sarcoma	0.000692	0.0014	CcSEcCtD
Levonorgestrel—Anorexia—Etoposide—sarcoma	0.000692	0.0014	CcSEcCtD
Levonorgestrel—Diarrhoea—Thiotepa—sarcoma	0.000691	0.0014	CcSEcCtD
Levonorgestrel—Body temperature increased—Mitoxantrone—sarcoma	0.00069	0.00139	CcSEcCtD
Levonorgestrel—Abdominal pain—Mitoxantrone—sarcoma	0.00069	0.00139	CcSEcCtD
Levonorgestrel—Bronchitis—Epirubicin—sarcoma	0.000688	0.00139	CcSEcCtD
Levonorgestrel—Diarrhoea—Dactinomycin—sarcoma	0.000686	0.00139	CcSEcCtD
Levonorgestrel—PGR—Signaling by ERBB4—CREB1—sarcoma	0.000682	0.00328	CbGpPWpGaD
Levonorgestrel—ESR1—Aryl Hydrocarbon Receptor—SRC—sarcoma	0.000671	0.00323	CbGpPWpGaD
Levonorgestrel—Dysuria—Epirubicin—sarcoma	0.000669	0.00135	CcSEcCtD
Levonorgestrel—Dizziness—Thiotepa—sarcoma	0.000668	0.00135	CcSEcCtD
Levonorgestrel—Abdominal distension—Doxorubicin—sarcoma	0.000666	0.00135	CcSEcCtD
Levonorgestrel—Upper respiratory tract infection—Epirubicin—sarcoma	0.000665	0.00134	CcSEcCtD
Levonorgestrel—ESR1—Regulation of nuclear SMAD2/3 signaling—CREB1—sarcoma	0.000662	0.00319	CbGpPWpGaD
Levonorgestrel—Influenza—Doxorubicin—sarcoma	0.000662	0.00134	CcSEcCtD
Levonorgestrel—Asthma—Doxorubicin—sarcoma	0.000662	0.00134	CcSEcCtD
Levonorgestrel—Pollakiuria—Epirubicin—sarcoma	0.000661	0.00133	CcSEcCtD
Levonorgestrel—Hypersensitivity—Vincristine—sarcoma	0.00066	0.00133	CcSEcCtD
Levonorgestrel—AR—Androgen receptor signaling pathway—MDM2—sarcoma	0.000659	0.00318	CbGpPWpGaD
Levonorgestrel—ESR1—Aryl Hydrocarbon Receptor—VEGFA—sarcoma	0.000654	0.00315	CbGpPWpGaD
Levonorgestrel—Weight increased—Epirubicin—sarcoma	0.000651	0.00131	CcSEcCtD
Levonorgestrel—Weight decreased—Epirubicin—sarcoma	0.000647	0.00131	CcSEcCtD
Levonorgestrel—ESR1—FOXM1 transcription factor network—MYC—sarcoma	0.000647	0.00312	CbGpPWpGaD
Levonorgestrel—Dyspnoea—Etoposide—sarcoma	0.000647	0.00131	CcSEcCtD
Levonorgestrel—ESR1—Aryl Hydrocarbon Receptor—NRAS—sarcoma	0.000646	0.00311	CbGpPWpGaD
Levonorgestrel—Somnolence—Etoposide—sarcoma	0.000645	0.0013	CcSEcCtD
Levonorgestrel—Hypersensitivity—Mitoxantrone—sarcoma	0.000643	0.0013	CcSEcCtD
Levonorgestrel—Asthenia—Vincristine—sarcoma	0.000643	0.0013	CcSEcCtD
Levonorgestrel—Vomiting—Thiotepa—sarcoma	0.000642	0.0013	CcSEcCtD
Levonorgestrel—Pneumonia—Epirubicin—sarcoma	0.000641	0.0013	CcSEcCtD
Levonorgestrel—Infestation NOS—Epirubicin—sarcoma	0.000638	0.00129	CcSEcCtD
Levonorgestrel—Infestation—Epirubicin—sarcoma	0.000638	0.00129	CcSEcCtD
Levonorgestrel—Vomiting—Dactinomycin—sarcoma	0.000637	0.00129	CcSEcCtD
Levonorgestrel—Rash—Thiotepa—sarcoma	0.000637	0.00129	CcSEcCtD
Levonorgestrel—Bronchitis—Doxorubicin—sarcoma	0.000636	0.00129	CcSEcCtD
Levonorgestrel—Dermatitis—Thiotepa—sarcoma	0.000636	0.00129	CcSEcCtD
Levonorgestrel—ESR1—LKB1 signaling events—MYC—sarcoma	0.000635	0.00306	CbGpPWpGaD
Levonorgestrel—Headache—Thiotepa—sarcoma	0.000633	0.00128	CcSEcCtD
Levonorgestrel—Rash—Dactinomycin—sarcoma	0.000632	0.00128	CcSEcCtD
Levonorgestrel—Decreased appetite—Etoposide—sarcoma	0.000631	0.00127	CcSEcCtD
Levonorgestrel—Gastrointestinal disorder—Etoposide—sarcoma	0.000626	0.00127	CcSEcCtD
Levonorgestrel—Asthenia—Mitoxantrone—sarcoma	0.000626	0.00126	CcSEcCtD
Levonorgestrel—Fatigue—Etoposide—sarcoma	0.000626	0.00126	CcSEcCtD
Levonorgestrel—AR—Regulation of nuclear beta catenin signaling and target gene transcription—CCND1—sarcoma	0.000625	0.00301	CbGpPWpGaD
Levonorgestrel—CYP3A4—Constitutive Androstane Receptor Pathway—FOXO1—sarcoma	0.000625	0.00301	CbGpPWpGaD
Levonorgestrel—AR—Regulation of nuclear beta catenin signaling and target gene transcription—JUN—sarcoma	0.000624	0.00301	CbGpPWpGaD
Levonorgestrel—Pain—Etoposide—sarcoma	0.00062	0.00125	CcSEcCtD
Levonorgestrel—Constipation—Etoposide—sarcoma	0.00062	0.00125	CcSEcCtD
Levonorgestrel—Urinary tract infection—Epirubicin—sarcoma	0.00062	0.00125	CcSEcCtD
Levonorgestrel—SRD5A1—Metabolism—PLCG1—sarcoma	0.000619	0.00298	CbGpPWpGaD
Levonorgestrel—CYP19A1—Integrated Breast Cancer Pathway—FOXO1—sarcoma	0.000619	0.00298	CbGpPWpGaD
Levonorgestrel—AR—Regulation of nuclear beta catenin signaling and target gene transcription—CTNNB1—sarcoma	0.000619	0.00298	CbGpPWpGaD
Levonorgestrel—Dysuria—Doxorubicin—sarcoma	0.000619	0.00125	CcSEcCtD
Levonorgestrel—AR—Regulation of nuclear SMAD2/3 signaling—JUN—sarcoma	0.000618	0.00298	CbGpPWpGaD
Levonorgestrel—Upper respiratory tract infection—Doxorubicin—sarcoma	0.000615	0.00124	CcSEcCtD
Levonorgestrel—ESR1—Signaling mediated by p38-alpha and p38-beta—TP53—sarcoma	0.000615	0.00296	CbGpPWpGaD
Levonorgestrel—ESR1—ATF-2 transcription factor network—CCND1—sarcoma	0.000615	0.00296	CbGpPWpGaD
Levonorgestrel—ESR1—ATF-2 transcription factor network—JUN—sarcoma	0.000613	0.00295	CbGpPWpGaD
Levonorgestrel—Diarrhoea—Vincristine—sarcoma	0.000613	0.00124	CcSEcCtD
Levonorgestrel—Pollakiuria—Doxorubicin—sarcoma	0.000611	0.00123	CcSEcCtD
Levonorgestrel—ESR1—Plasma membrane estrogen receptor signaling—KRAS—sarcoma	0.000609	0.00294	CbGpPWpGaD
Levonorgestrel—PGR—Gene Expression—FUS—sarcoma	0.000604	0.00291	CbGpPWpGaD
Levonorgestrel—Weight increased—Doxorubicin—sarcoma	0.000602	0.00122	CcSEcCtD
Levonorgestrel—ESR1—Aryl Hydrocarbon Receptor—MYC—sarcoma	0.000602	0.0029	CbGpPWpGaD
Levonorgestrel—Nausea—Thiotepa—sarcoma	0.0006	0.00121	CcSEcCtD
Levonorgestrel—Weight decreased—Doxorubicin—sarcoma	0.000599	0.00121	CcSEcCtD
Levonorgestrel—Sinusitis—Epirubicin—sarcoma	0.000598	0.00121	CcSEcCtD
Levonorgestrel—Diarrhoea—Mitoxantrone—sarcoma	0.000597	0.00121	CcSEcCtD
Levonorgestrel—Nausea—Dactinomycin—sarcoma	0.000595	0.0012	CcSEcCtD
Levonorgestrel—Pneumonia—Doxorubicin—sarcoma	0.000593	0.0012	CcSEcCtD
Levonorgestrel—Gastrointestinal pain—Etoposide—sarcoma	0.000593	0.0012	CcSEcCtD
Levonorgestrel—Dizziness—Vincristine—sarcoma	0.000592	0.0012	CcSEcCtD
Levonorgestrel—Infestation NOS—Doxorubicin—sarcoma	0.00059	0.00119	CcSEcCtD
Levonorgestrel—Infestation—Doxorubicin—sarcoma	0.00059	0.00119	CcSEcCtD
Levonorgestrel—ESR1—Aryl Hydrocarbon Receptor—EGFR—sarcoma	0.000588	0.00283	CbGpPWpGaD
Levonorgestrel—AR—Integrated Pancreatic Cancer Pathway—PDGFRA—sarcoma	0.000586	0.00282	CbGpPWpGaD
Levonorgestrel—Urticaria—Etoposide—sarcoma	0.000576	0.00116	CcSEcCtD
Levonorgestrel—ESR1—Validated nuclear estrogen receptor alpha network—CCND1—sarcoma	0.000576	0.00277	CbGpPWpGaD
Levonorgestrel—Haemoglobin—Epirubicin—sarcoma	0.000575	0.00116	CcSEcCtD
Levonorgestrel—ESR1—Validated nuclear estrogen receptor alpha network—JUN—sarcoma	0.000575	0.00277	CbGpPWpGaD
Levonorgestrel—AR—Androgen receptor signaling pathway—CCND1—sarcoma	0.000574	0.00277	CbGpPWpGaD
Levonorgestrel—Rhinitis—Epirubicin—sarcoma	0.000574	0.00116	CcSEcCtD
Levonorgestrel—Abdominal pain—Etoposide—sarcoma	0.000574	0.00116	CcSEcCtD
Levonorgestrel—Body temperature increased—Etoposide—sarcoma	0.000574	0.00116	CcSEcCtD
Levonorgestrel—Urinary tract infection—Doxorubicin—sarcoma	0.000574	0.00116	CcSEcCtD
Levonorgestrel—AR—Androgen receptor signaling pathway—JUN—sarcoma	0.000573	0.00276	CbGpPWpGaD
Levonorgestrel—Haemorrhage—Epirubicin—sarcoma	0.000572	0.00116	CcSEcCtD
Levonorgestrel—Hypoaesthesia—Epirubicin—sarcoma	0.00057	0.00115	CcSEcCtD
Levonorgestrel—Vomiting—Vincristine—sarcoma	0.000569	0.00115	CcSEcCtD
Levonorgestrel—AR—Androgen receptor signaling pathway—CTNNB1—sarcoma	0.000569	0.00274	CbGpPWpGaD
Levonorgestrel—Pharyngitis—Epirubicin—sarcoma	0.000568	0.00115	CcSEcCtD
Levonorgestrel—Urinary tract disorder—Epirubicin—sarcoma	0.000565	0.00114	CcSEcCtD
Levonorgestrel—Rash—Vincristine—sarcoma	0.000565	0.00114	CcSEcCtD
Levonorgestrel—Dermatitis—Vincristine—sarcoma	0.000564	0.00114	CcSEcCtD
Levonorgestrel—PGR—Signaling by ERBB4—MDM2—sarcoma	0.000564	0.00272	CbGpPWpGaD
Levonorgestrel—ESR1—Regulation of Telomerase—IL2—sarcoma	0.000563	0.00271	CbGpPWpGaD
Levonorgestrel—Connective tissue disorder—Epirubicin—sarcoma	0.000563	0.00114	CcSEcCtD
Levonorgestrel—Urethral disorder—Epirubicin—sarcoma	0.000561	0.00113	CcSEcCtD
Levonorgestrel—Headache—Vincristine—sarcoma	0.000561	0.00113	CcSEcCtD
Levonorgestrel—ESR1—Aryl Hydrocarbon Receptor—KRAS—sarcoma	0.000556	0.00268	CbGpPWpGaD
Levonorgestrel—Vomiting—Mitoxantrone—sarcoma	0.000555	0.00112	CcSEcCtD
Levonorgestrel—ESR1—Integrated Breast Cancer Pathway—FOXO1—sarcoma	0.000554	0.00267	CbGpPWpGaD
Levonorgestrel—Sinusitis—Doxorubicin—sarcoma	0.000554	0.00112	CcSEcCtD
Levonorgestrel—Visual impairment—Epirubicin—sarcoma	0.000552	0.00111	CcSEcCtD
Levonorgestrel—ESR1—Signaling by ERBB4—FOXO1—sarcoma	0.000552	0.00266	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling by ERBB4—PDGFRB—sarcoma	0.000551	0.00265	CbGpPWpGaD
Levonorgestrel—Rash—Mitoxantrone—sarcoma	0.00055	0.00111	CcSEcCtD
Levonorgestrel—ESR1—AP-1 transcription factor network—IL2—sarcoma	0.00055	0.00265	CbGpPWpGaD
Levonorgestrel—Dermatitis—Mitoxantrone—sarcoma	0.000549	0.00111	CcSEcCtD
Levonorgestrel—ESR1—Regulation of Telomerase—CCND1—sarcoma	0.000549	0.00264	CbGpPWpGaD
Levonorgestrel—ESR1—Regulation of Telomerase—JUN—sarcoma	0.000547	0.00264	CbGpPWpGaD
Levonorgestrel—Headache—Mitoxantrone—sarcoma	0.000546	0.0011	CcSEcCtD
Levonorgestrel—ESR1—Signaling by ERBB4—PDGFRA—sarcoma	0.000542	0.00261	CbGpPWpGaD
Levonorgestrel—Erythema multiforme—Epirubicin—sarcoma	0.000541	0.00109	CcSEcCtD
Levonorgestrel—ESR1—AP-1 transcription factor network—CCND1—sarcoma	0.000536	0.00258	CbGpPWpGaD
Levonorgestrel—Eye disorder—Epirubicin—sarcoma	0.000535	0.00108	CcSEcCtD
Levonorgestrel—ESR1—AP-1 transcription factor network—JUN—sarcoma	0.000535	0.00258	CbGpPWpGaD
Levonorgestrel—Hypersensitivity—Etoposide—sarcoma	0.000535	0.00108	CcSEcCtD
Levonorgestrel—Haemoglobin—Doxorubicin—sarcoma	0.000532	0.00108	CcSEcCtD
Levonorgestrel—Nausea—Vincristine—sarcoma	0.000532	0.00107	CcSEcCtD
Levonorgestrel—Cardiac disorder—Epirubicin—sarcoma	0.000531	0.00107	CcSEcCtD
Levonorgestrel—Rhinitis—Doxorubicin—sarcoma	0.000531	0.00107	CcSEcCtD
Levonorgestrel—ESR1—AP-1 transcription factor network—CTNNB1—sarcoma	0.000531	0.00256	CbGpPWpGaD
Levonorgestrel—Haemorrhage—Doxorubicin—sarcoma	0.00053	0.00107	CcSEcCtD
Levonorgestrel—Hypoaesthesia—Doxorubicin—sarcoma	0.000527	0.00106	CcSEcCtD
Levonorgestrel—Pharyngitis—Doxorubicin—sarcoma	0.000526	0.00106	CcSEcCtD
Levonorgestrel—Urinary tract disorder—Doxorubicin—sarcoma	0.000523	0.00106	CcSEcCtD
Levonorgestrel—AR—Integrated Breast Cancer Pathway—CREB1—sarcoma	0.000522	0.00251	CbGpPWpGaD
Levonorgestrel—ESR1—LKB1 signaling events—TP53—sarcoma	0.000521	0.00251	CbGpPWpGaD
Levonorgestrel—Asthenia—Etoposide—sarcoma	0.000521	0.00105	CcSEcCtD
Levonorgestrel—Connective tissue disorder—Doxorubicin—sarcoma	0.000521	0.00105	CcSEcCtD
Levonorgestrel—Urethral disorder—Doxorubicin—sarcoma	0.000519	0.00105	CcSEcCtD
Levonorgestrel—Nausea—Mitoxantrone—sarcoma	0.000518	0.00105	CcSEcCtD
Levonorgestrel—ESR1—Plasma membrane estrogen receptor signaling—HRAS—sarcoma	0.000518	0.0025	CbGpPWpGaD
Levonorgestrel—Immune system disorder—Epirubicin—sarcoma	0.000517	0.00104	CcSEcCtD
Levonorgestrel—Mediastinal disorder—Epirubicin—sarcoma	0.000516	0.00104	CcSEcCtD
Levonorgestrel—AR—Androgen receptor signaling pathway—SRC—sarcoma	0.000514	0.00248	CbGpPWpGaD
Levonorgestrel—Pruritus—Etoposide—sarcoma	0.000513	0.00104	CcSEcCtD
Levonorgestrel—Arrhythmia—Epirubicin—sarcoma	0.000511	0.00103	CcSEcCtD
Levonorgestrel—Visual impairment—Doxorubicin—sarcoma	0.00051	0.00103	CcSEcCtD
Levonorgestrel—AR—SIDS Susceptibility Pathways—CREB1—sarcoma	0.000509	0.00245	CbGpPWpGaD
Levonorgestrel—ESR1—Leptin signaling pathway—CCND1—sarcoma	0.000507	0.00244	CbGpPWpGaD
Levonorgestrel—Alopecia—Epirubicin—sarcoma	0.000506	0.00102	CcSEcCtD
Levonorgestrel—AR—Regulation of nuclear beta catenin signaling and target gene transcription—MYC—sarcoma	0.000502	0.00242	CbGpPWpGaD
Levonorgestrel—Mental disorder—Epirubicin—sarcoma	0.000502	0.00101	CcSEcCtD
Levonorgestrel—Erythema multiforme—Doxorubicin—sarcoma	0.000501	0.00101	CcSEcCtD
Levonorgestrel—Malnutrition—Epirubicin—sarcoma	0.000498	0.00101	CcSEcCtD
Levonorgestrel—Erythema—Epirubicin—sarcoma	0.000498	0.00101	CcSEcCtD
Levonorgestrel—AR—Regulation of nuclear SMAD2/3 signaling—MYC—sarcoma	0.000497	0.00239	CbGpPWpGaD
Levonorgestrel—Diarrhoea—Etoposide—sarcoma	0.000496	0.001	CcSEcCtD
Levonorgestrel—Eye disorder—Doxorubicin—sarcoma	0.000495	0.001	CcSEcCtD
Levonorgestrel—Cardiac disorder—Doxorubicin—sarcoma	0.000492	0.000993	CcSEcCtD
Levonorgestrel—Flatulence—Epirubicin—sarcoma	0.000491	0.000992	CcSEcCtD
Levonorgestrel—Tension—Epirubicin—sarcoma	0.000489	0.000988	CcSEcCtD
Levonorgestrel—Nervousness—Epirubicin—sarcoma	0.000484	0.000978	CcSEcCtD
Levonorgestrel—Back pain—Epirubicin—sarcoma	0.000482	0.000974	CcSEcCtD
Levonorgestrel—Dizziness—Etoposide—sarcoma	0.00048	0.000969	CcSEcCtD
Levonorgestrel—Muscle spasms—Epirubicin—sarcoma	0.000479	0.000968	CcSEcCtD
Levonorgestrel—Immune system disorder—Doxorubicin—sarcoma	0.000478	0.000966	CcSEcCtD
Levonorgestrel—Mediastinal disorder—Doxorubicin—sarcoma	0.000477	0.000964	CcSEcCtD
Levonorgestrel—ESR1—Regulation of nuclear SMAD2/3 signaling—JUN—sarcoma	0.000476	0.00229	CbGpPWpGaD
Levonorgestrel—Arrhythmia—Doxorubicin—sarcoma	0.000473	0.000956	CcSEcCtD
Levonorgestrel—ESR1—Aryl Hydrocarbon Receptor—HRAS—sarcoma	0.000473	0.00228	CbGpPWpGaD
Levonorgestrel—Alopecia—Doxorubicin—sarcoma	0.000468	0.000945	CcSEcCtD
Levonorgestrel—Mental disorder—Doxorubicin—sarcoma	0.000464	0.000937	CcSEcCtD
Levonorgestrel—ESR1—Validated nuclear estrogen receptor alpha network—MYC—sarcoma	0.000462	0.00223	CbGpPWpGaD
Levonorgestrel—Vomiting—Etoposide—sarcoma	0.000461	0.000932	CcSEcCtD
Levonorgestrel—Malnutrition—Doxorubicin—sarcoma	0.000461	0.000931	CcSEcCtD
Levonorgestrel—Erythema—Doxorubicin—sarcoma	0.000461	0.000931	CcSEcCtD
Levonorgestrel—Anaemia—Epirubicin—sarcoma	0.000461	0.00093	CcSEcCtD
Levonorgestrel—AR—Gene Expression—FUS—sarcoma	0.00046	0.00222	CbGpPWpGaD
Levonorgestrel—Rash—Etoposide—sarcoma	0.000457	0.000924	CcSEcCtD
Levonorgestrel—Dermatitis—Etoposide—sarcoma	0.000457	0.000923	CcSEcCtD
Levonorgestrel—Headache—Etoposide—sarcoma	0.000455	0.000918	CcSEcCtD
Levonorgestrel—Flatulence—Doxorubicin—sarcoma	0.000454	0.000918	CcSEcCtD
Levonorgestrel—ESR1—Leptin signaling pathway—SRC—sarcoma	0.000454	0.00219	CbGpPWpGaD
Levonorgestrel—Tension—Doxorubicin—sarcoma	0.000452	0.000914	CcSEcCtD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—PDGFRA—sarcoma	0.000451	0.00217	CbGpPWpGaD
Levonorgestrel—AR—Androgen receptor signaling pathway—EGFR—sarcoma	0.000451	0.00217	CbGpPWpGaD
Levonorgestrel—CYP19A1—Integrated Breast Cancer Pathway—CREB1—sarcoma	0.000449	0.00216	CbGpPWpGaD
Levonorgestrel—Nervousness—Doxorubicin—sarcoma	0.000448	0.000905	CcSEcCtD
Levonorgestrel—Vertigo—Epirubicin—sarcoma	0.000448	0.000904	CcSEcCtD
Levonorgestrel—Syncope—Epirubicin—sarcoma	0.000447	0.000903	CcSEcCtD
Levonorgestrel—Back pain—Doxorubicin—sarcoma	0.000446	0.000901	CcSEcCtD
Levonorgestrel—Muscle spasms—Doxorubicin—sarcoma	0.000443	0.000895	CcSEcCtD
Levonorgestrel—Palpitations—Epirubicin—sarcoma	0.00044	0.00089	CcSEcCtD
Levonorgestrel—ESR1—Regulation of Telomerase—MYC—sarcoma	0.00044	0.00212	CbGpPWpGaD
Levonorgestrel—Loss of consciousness—Epirubicin—sarcoma	0.000438	0.000885	CcSEcCtD
Levonorgestrel—Cough—Epirubicin—sarcoma	0.000435	0.000878	CcSEcCtD
Levonorgestrel—AR—Integrated Pancreatic Cancer Pathway—CREB1—sarcoma	0.000433	0.00208	CbGpPWpGaD
Levonorgestrel—AR—Integrated Breast Cancer Pathway—MDM2—sarcoma	0.000432	0.00208	CbGpPWpGaD
Levonorgestrel—Nausea—Etoposide—sarcoma	0.000431	0.000871	CcSEcCtD
Levonorgestrel—ESR1—Regulation of Telomerase—EGFR—sarcoma	0.00043	0.00207	CbGpPWpGaD
Levonorgestrel—Hypertension—Epirubicin—sarcoma	0.00043	0.000869	CcSEcCtD
Levonorgestrel—ESR1—AP-1 transcription factor network—MYC—sarcoma	0.00043	0.00207	CbGpPWpGaD
Levonorgestrel—Anaemia—Doxorubicin—sarcoma	0.000426	0.000861	CcSEcCtD
Levonorgestrel—Chest pain—Epirubicin—sarcoma	0.000424	0.000857	CcSEcCtD
Levonorgestrel—Myalgia—Epirubicin—sarcoma	0.000424	0.000857	CcSEcCtD
Levonorgestrel—PGR—Signaling by ERBB4—NRAS—sarcoma	0.000423	0.00204	CbGpPWpGaD
Levonorgestrel—Anxiety—Epirubicin—sarcoma	0.000423	0.000854	CcSEcCtD
Levonorgestrel—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—sarcoma	0.000421	0.000851	CcSEcCtD
Levonorgestrel—ESR1—Signaling by ERBB4—KIT—sarcoma	0.00042	0.00202	CbGpPWpGaD
Levonorgestrel—Discomfort—Epirubicin—sarcoma	0.000419	0.000847	CcSEcCtD
Levonorgestrel—Vertigo—Doxorubicin—sarcoma	0.000414	0.000837	CcSEcCtD
Levonorgestrel—Syncope—Doxorubicin—sarcoma	0.000413	0.000835	CcSEcCtD
Levonorgestrel—Palpitations—Doxorubicin—sarcoma	0.000407	0.000823	CcSEcCtD
Levonorgestrel—Oedema—Epirubicin—sarcoma	0.000407	0.000822	CcSEcCtD
Levonorgestrel—Loss of consciousness—Doxorubicin—sarcoma	0.000405	0.000819	CcSEcCtD
Levonorgestrel—Infection—Epirubicin—sarcoma	0.000404	0.000816	CcSEcCtD
Levonorgestrel—Cough—Doxorubicin—sarcoma	0.000402	0.000813	CcSEcCtD
Levonorgestrel—ESR1—Integrated Breast Cancer Pathway—CREB1—sarcoma	0.000402	0.00194	CbGpPWpGaD
Levonorgestrel—Shock—Epirubicin—sarcoma	0.0004	0.000808	CcSEcCtD
Levonorgestrel—ESR1—Signaling by ERBB4—CREB1—sarcoma	0.0004	0.00193	CbGpPWpGaD
Levonorgestrel—Nervous system disorder—Epirubicin—sarcoma	0.000399	0.000806	CcSEcCtD
Levonorgestrel—Hypertension—Doxorubicin—sarcoma	0.000398	0.000804	CcSEcCtD
Levonorgestrel—Skin disorder—Epirubicin—sarcoma	0.000395	0.000798	CcSEcCtD
Levonorgestrel—Hyperhidrosis—Epirubicin—sarcoma	0.000393	0.000794	CcSEcCtD
Levonorgestrel—Chest pain—Doxorubicin—sarcoma	0.000393	0.000793	CcSEcCtD
Levonorgestrel—Myalgia—Doxorubicin—sarcoma	0.000393	0.000793	CcSEcCtD
Levonorgestrel—Anxiety—Doxorubicin—sarcoma	0.000391	0.00079	CcSEcCtD
Levonorgestrel—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—sarcoma	0.00039	0.000787	CcSEcCtD
Levonorgestrel—Discomfort—Doxorubicin—sarcoma	0.000388	0.000783	CcSEcCtD
Levonorgestrel—Anorexia—Epirubicin—sarcoma	0.000388	0.000783	CcSEcCtD
Levonorgestrel—PGR—Signaling by ERBB4—EGFR—sarcoma	0.000385	0.00186	CbGpPWpGaD
Levonorgestrel—ESR1—Regulation of nuclear SMAD2/3 signaling—MYC—sarcoma	0.000383	0.00184	CbGpPWpGaD
Levonorgestrel—Oedema—Doxorubicin—sarcoma	0.000376	0.00076	CcSEcCtD
Levonorgestrel—AR—Integrated Breast Cancer Pathway—CCND1—sarcoma	0.000376	0.00181	CbGpPWpGaD
Levonorgestrel—AR—Integrated Breast Cancer Pathway—JUN—sarcoma	0.000375	0.00181	CbGpPWpGaD
Levonorgestrel—Infection—Doxorubicin—sarcoma	0.000374	0.000755	CcSEcCtD
Levonorgestrel—AR—Integrated Breast Cancer Pathway—CTNNB1—sarcoma	0.000373	0.00179	CbGpPWpGaD
Levonorgestrel—CYP19A1—Integrated Breast Cancer Pathway—MDM2—sarcoma	0.000372	0.00179	CbGpPWpGaD
Levonorgestrel—Musculoskeletal discomfort—Epirubicin—sarcoma	0.000371	0.000748	CcSEcCtD
Levonorgestrel—Shock—Doxorubicin—sarcoma	0.00037	0.000748	CcSEcCtD
Levonorgestrel—Nervous system disorder—Doxorubicin—sarcoma	0.000369	0.000745	CcSEcCtD
Levonorgestrel—Insomnia—Epirubicin—sarcoma	0.000368	0.000743	CcSEcCtD
Levonorgestrel—AR—SIDS Susceptibility Pathways—JUN—sarcoma	0.000366	0.00176	CbGpPWpGaD
Levonorgestrel—Skin disorder—Doxorubicin—sarcoma	0.000366	0.000738	CcSEcCtD
Levonorgestrel—PGR—Signaling by ERBB4—KRAS—sarcoma	0.000364	0.00175	CbGpPWpGaD
Levonorgestrel—Hyperhidrosis—Doxorubicin—sarcoma	0.000364	0.000735	CcSEcCtD
Levonorgestrel—AR—SIDS Susceptibility Pathways—CTNNB1—sarcoma	0.000363	0.00175	CbGpPWpGaD
Levonorgestrel—Dyspnoea—Epirubicin—sarcoma	0.000363	0.000732	CcSEcCtD
Levonorgestrel—Somnolence—Epirubicin—sarcoma	0.000362	0.00073	CcSEcCtD
Levonorgestrel—Anorexia—Doxorubicin—sarcoma	0.000359	0.000725	CcSEcCtD
Levonorgestrel—Dyspepsia—Epirubicin—sarcoma	0.000358	0.000723	CcSEcCtD
Levonorgestrel—AR—Integrated Pancreatic Cancer Pathway—MDM2—sarcoma	0.000358	0.00172	CbGpPWpGaD
Levonorgestrel—ESR1—Gene Expression—FUS—sarcoma	0.000354	0.00171	CbGpPWpGaD
Levonorgestrel—Decreased appetite—Epirubicin—sarcoma	0.000354	0.000714	CcSEcCtD
Levonorgestrel—ESR1—AP-1 transcription factor network—TP53—sarcoma	0.000353	0.0017	CbGpPWpGaD
Levonorgestrel—Gastrointestinal disorder—Epirubicin—sarcoma	0.000351	0.000709	CcSEcCtD
Levonorgestrel—Fatigue—Epirubicin—sarcoma	0.000351	0.000708	CcSEcCtD
Levonorgestrel—Constipation—Epirubicin—sarcoma	0.000348	0.000703	CcSEcCtD
Levonorgestrel—Pain—Epirubicin—sarcoma	0.000348	0.000703	CcSEcCtD
Levonorgestrel—Musculoskeletal discomfort—Doxorubicin—sarcoma	0.000343	0.000693	CcSEcCtD
Levonorgestrel—Insomnia—Doxorubicin—sarcoma	0.00034	0.000688	CcSEcCtD
Levonorgestrel—Dyspnoea—Doxorubicin—sarcoma	0.000335	0.000678	CcSEcCtD
Levonorgestrel—Somnolence—Doxorubicin—sarcoma	0.000335	0.000676	CcSEcCtD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—CREB1—sarcoma	0.000333	0.00161	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Breast Cancer Pathway—MDM2—sarcoma	0.000333	0.0016	CbGpPWpGaD
Levonorgestrel—Gastrointestinal pain—Epirubicin—sarcoma	0.000333	0.000672	CcSEcCtD
Levonorgestrel—Dyspepsia—Doxorubicin—sarcoma	0.000331	0.000669	CcSEcCtD
Levonorgestrel—ESR1—Signaling by ERBB4—MDM2—sarcoma	0.000331	0.00159	CbGpPWpGaD
Levonorgestrel—AR—Integrated Breast Cancer Pathway—VEGFA—sarcoma	0.000328	0.00158	CbGpPWpGaD
Levonorgestrel—Decreased appetite—Doxorubicin—sarcoma	0.000327	0.000661	CcSEcCtD
Levonorgestrel—Gastrointestinal disorder—Doxorubicin—sarcoma	0.000325	0.000656	CcSEcCtD
Levonorgestrel—Fatigue—Doxorubicin—sarcoma	0.000324	0.000655	CcSEcCtD
Levonorgestrel—CYP19A1—Integrated Breast Cancer Pathway—CCND1—sarcoma	0.000324	0.00156	CbGpPWpGaD
Levonorgestrel—Urticaria—Epirubicin—sarcoma	0.000323	0.000653	CcSEcCtD
Levonorgestrel—CYP19A1—Integrated Breast Cancer Pathway—JUN—sarcoma	0.000323	0.00156	CbGpPWpGaD
Levonorgestrel—Constipation—Doxorubicin—sarcoma	0.000322	0.00065	CcSEcCtD
Levonorgestrel—Pain—Doxorubicin—sarcoma	0.000322	0.00065	CcSEcCtD
Levonorgestrel—Body temperature increased—Epirubicin—sarcoma	0.000322	0.000649	CcSEcCtD
Levonorgestrel—Abdominal pain—Epirubicin—sarcoma	0.000322	0.000649	CcSEcCtD
Levonorgestrel—CYP19A1—Integrated Breast Cancer Pathway—CTNNB1—sarcoma	0.000321	0.00154	CbGpPWpGaD
Levonorgestrel—ESR1—Leptin signaling pathway—HRAS—sarcoma	0.00032	0.00154	CbGpPWpGaD
Levonorgestrel—AR—SIDS Susceptibility Pathways—VEGFA—sarcoma	0.00032	0.00154	CbGpPWpGaD
Levonorgestrel—AR—Integrated Pancreatic Cancer Pathway—CCND1—sarcoma	0.000312	0.0015	CbGpPWpGaD
Levonorgestrel—AR—Integrated Pancreatic Cancer Pathway—JUN—sarcoma	0.000311	0.0015	CbGpPWpGaD
Levonorgestrel—PGR—Signaling by ERBB4—HRAS—sarcoma	0.000309	0.00149	CbGpPWpGaD
Levonorgestrel—AR—Integrated Pancreatic Cancer Pathway—CTNNB1—sarcoma	0.000309	0.00149	CbGpPWpGaD
Levonorgestrel—Gastrointestinal pain—Doxorubicin—sarcoma	0.000308	0.000622	CcSEcCtD
Levonorgestrel—AR—Integrated Breast Cancer Pathway—MYC—sarcoma	0.000302	0.00145	CbGpPWpGaD
Levonorgestrel—Hypersensitivity—Epirubicin—sarcoma	0.0003	0.000605	CcSEcCtD
Levonorgestrel—Urticaria—Doxorubicin—sarcoma	0.000299	0.000604	CcSEcCtD
Levonorgestrel—Body temperature increased—Doxorubicin—sarcoma	0.000297	0.000601	CcSEcCtD
Levonorgestrel—Abdominal pain—Doxorubicin—sarcoma	0.000297	0.000601	CcSEcCtD
Levonorgestrel—AR—Integrated Breast Cancer Pathway—EGFR—sarcoma	0.000295	0.00142	CbGpPWpGaD
Levonorgestrel—Asthenia—Epirubicin—sarcoma	0.000292	0.000589	CcSEcCtD
Levonorgestrel—ESR1—Integrated Breast Cancer Pathway—CCND1—sarcoma	0.00029	0.0014	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Breast Cancer Pathway—JUN—sarcoma	0.000289	0.00139	CbGpPWpGaD
Levonorgestrel—Pruritus—Epirubicin—sarcoma	0.000288	0.000581	CcSEcCtD
Levonorgestrel—ESR1—Integrated Breast Cancer Pathway—CTNNB1—sarcoma	0.000287	0.00138	CbGpPWpGaD
Levonorgestrel—CYP19A1—Integrated Breast Cancer Pathway—VEGFA—sarcoma	0.000282	0.00136	CbGpPWpGaD
Levonorgestrel—CYP3A4—Tryptophan metabolism—MDM2—sarcoma	0.000281	0.00135	CbGpPWpGaD
Levonorgestrel—AR—Integrated Pancreatic Cancer Pathway—SRC—sarcoma	0.000279	0.00134	CbGpPWpGaD
Levonorgestrel—AR—Integrated Breast Cancer Pathway—KRAS—sarcoma	0.000279	0.00134	CbGpPWpGaD
Levonorgestrel—Diarrhoea—Epirubicin—sarcoma	0.000278	0.000562	CcSEcCtD
Levonorgestrel—Hypersensitivity—Doxorubicin—sarcoma	0.000277	0.00056	CcSEcCtD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—MDM2—sarcoma	0.000276	0.00133	CbGpPWpGaD
Levonorgestrel—AR—Integrated Pancreatic Cancer Pathway—VEGFA—sarcoma	0.000272	0.00131	CbGpPWpGaD
Levonorgestrel—Asthenia—Doxorubicin—sarcoma	0.00027	0.000545	CcSEcCtD
Levonorgestrel—Dizziness—Epirubicin—sarcoma	0.000269	0.000543	CcSEcCtD
Levonorgestrel—Pruritus—Doxorubicin—sarcoma	0.000266	0.000538	CcSEcCtD
Levonorgestrel—CYP19A1—Integrated Breast Cancer Pathway—MYC—sarcoma	0.00026	0.00125	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—TLE1—sarcoma	0.000259	0.00125	CbGpPWpGaD
Levonorgestrel—Vomiting—Epirubicin—sarcoma	0.000259	0.000522	CcSEcCtD
Levonorgestrel—Diarrhoea—Doxorubicin—sarcoma	0.000257	0.00052	CcSEcCtD
Levonorgestrel—Rash—Epirubicin—sarcoma	0.000256	0.000518	CcSEcCtD
Levonorgestrel—Dermatitis—Epirubicin—sarcoma	0.000256	0.000517	CcSEcCtD
Levonorgestrel—Headache—Epirubicin—sarcoma	0.000255	0.000515	CcSEcCtD
Levonorgestrel—CYP19A1—Integrated Breast Cancer Pathway—EGFR—sarcoma	0.000254	0.00122	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Breast Cancer Pathway—VEGFA—sarcoma	0.000253	0.00122	CbGpPWpGaD
Levonorgestrel—AR—Integrated Pancreatic Cancer Pathway—MYC—sarcoma	0.00025	0.0012	CbGpPWpGaD
Levonorgestrel—Dizziness—Doxorubicin—sarcoma	0.000249	0.000503	CcSEcCtD
Levonorgestrel—ESR1—Signaling by ERBB4—NRAS—sarcoma	0.000248	0.0012	CbGpPWpGaD
Levonorgestrel—AR—Integrated Breast Cancer Pathway—TP53—sarcoma	0.000248	0.00119	CbGpPWpGaD
Levonorgestrel—AR—Integrated Pancreatic Cancer Pathway—EGFR—sarcoma	0.000245	0.00118	CbGpPWpGaD
Levonorgestrel—Nausea—Epirubicin—sarcoma	0.000242	0.000488	CcSEcCtD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—CCND1—sarcoma	0.00024	0.00116	CbGpPWpGaD
Levonorgestrel—CYP19A1—Integrated Breast Cancer Pathway—KRAS—sarcoma	0.00024	0.00116	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—JUN—sarcoma	0.00024	0.00115	CbGpPWpGaD
Levonorgestrel—Vomiting—Doxorubicin—sarcoma	0.000239	0.000483	CcSEcCtD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—CTNNB1—sarcoma	0.000238	0.00115	CbGpPWpGaD
Levonorgestrel—Rash—Doxorubicin—sarcoma	0.000237	0.000479	CcSEcCtD
Levonorgestrel—Dermatitis—Doxorubicin—sarcoma	0.000237	0.000479	CcSEcCtD
Levonorgestrel—Headache—Doxorubicin—sarcoma	0.000236	0.000476	CcSEcCtD
Levonorgestrel—ESR1—Integrated Breast Cancer Pathway—MYC—sarcoma	0.000232	0.00112	CbGpPWpGaD
Levonorgestrel—AR—Integrated Pancreatic Cancer Pathway—KRAS—sarcoma	0.000231	0.00111	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Breast Cancer Pathway—EGFR—sarcoma	0.000227	0.0011	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling by ERBB4—EGFR—sarcoma	0.000226	0.00109	CbGpPWpGaD
Levonorgestrel—Nausea—Doxorubicin—sarcoma	0.000224	0.000452	CcSEcCtD
Levonorgestrel—PGR—Signaling Pathways—VEGFC—sarcoma	0.000218	0.00105	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—SRC—sarcoma	0.000215	0.00104	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Breast Cancer Pathway—KRAS—sarcoma	0.000215	0.00103	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling by ERBB4—KRAS—sarcoma	0.000214	0.00103	CbGpPWpGaD
Levonorgestrel—CYP19A1—Integrated Breast Cancer Pathway—TP53—sarcoma	0.000213	0.00103	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—VEGFA—sarcoma	0.000209	0.00101	CbGpPWpGaD
Levonorgestrel—AR—Integrated Pancreatic Cancer Pathway—TP53—sarcoma	0.000205	0.000989	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—MYC—sarcoma	0.000193	0.000928	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Breast Cancer Pathway—TP53—sarcoma	0.000191	0.00092	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—EGFR—sarcoma	0.000188	0.000908	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling by ERBB4—HRAS—sarcoma	0.000182	0.000875	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—KRAS—sarcoma	0.000178	0.000857	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—FLT1—sarcoma	0.000175	0.000841	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—PLCG1—sarcoma	0.000172	0.000826	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—CXCR4—sarcoma	0.000165	0.000794	CbGpPWpGaD
Levonorgestrel—PGR—Generic Transcription Pathway—MYC—sarcoma	0.000163	0.000785	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—ATF1—sarcoma	0.000163	0.000785	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—ENO2—sarcoma	0.000159	0.000764	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—TP53—sarcoma	0.000158	0.000762	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—HBA1—sarcoma	0.000158	0.000759	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—TLE1—sarcoma	0.000152	0.000732	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—PLCG1—sarcoma	0.000134	0.000648	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—VEGFC—sarcoma	0.000128	0.000617	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—IGF1R—sarcoma	0.000128	0.000616	CbGpPWpGaD
Levonorgestrel—AR—Generic Transcription Pathway—MYC—sarcoma	0.000124	0.000598	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—FOXO1—sarcoma	0.000122	0.000586	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—PDGFRB—sarcoma	0.000122	0.000585	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—PDGFRA—sarcoma	0.00012	0.000576	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—FLT1—sarcoma	0.000102	0.000493	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—PLCG1—sarcoma	0.000101	0.000485	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—KDR—sarcoma	0.000101	0.000485	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—CXCR4—sarcoma	9.67e-05	0.000466	CbGpPWpGaD
Levonorgestrel—ESR1—Generic Transcription Pathway—MYC—sarcoma	9.57e-05	0.000461	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—ATF1—sarcoma	9.56e-05	0.000461	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—KIT—sarcoma	9.27e-05	0.000447	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—CREB1—sarcoma	8.83e-05	0.000425	CbGpPWpGaD
Levonorgestrel—PGR—Gene Expression—MYC—sarcoma	7.85e-05	0.000378	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—IGF1R—sarcoma	7.51e-05	0.000362	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—MDM2—sarcoma	7.3e-05	0.000352	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—FOXO1—sarcoma	7.14e-05	0.000344	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—PDGFRB—sarcoma	7.13e-05	0.000344	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—PDGFRA—sarcoma	7.02e-05	0.000338	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—IL2—sarcoma	6.53e-05	0.000314	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—CCND1—sarcoma	6.36e-05	0.000306	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—JUN—sarcoma	6.35e-05	0.000306	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—CTNNB1—sarcoma	6.3e-05	0.000304	CbGpPWpGaD
Levonorgestrel—AR—Gene Expression—MYC—sarcoma	5.98e-05	0.000288	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—KDR—sarcoma	5.91e-05	0.000285	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—SRC—sarcoma	5.7e-05	0.000274	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—VEGFA—sarcoma	5.55e-05	0.000267	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—NRAS—sarcoma	5.48e-05	0.000264	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—KIT—sarcoma	5.44e-05	0.000262	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—CREB1—sarcoma	5.18e-05	0.00025	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—MYC—sarcoma	5.1e-05	0.000246	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—EGFR—sarcoma	4.99e-05	0.00024	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—KRAS—sarcoma	4.72e-05	0.000227	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—ENO2—sarcoma	4.63e-05	0.000223	CbGpPWpGaD
Levonorgestrel—ESR1—Gene Expression—MYC—sarcoma	4.61e-05	0.000222	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—HBA1—sarcoma	4.6e-05	0.000221	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—MDM2—sarcoma	4.29e-05	0.000207	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—TP53—sarcoma	4.19e-05	0.000202	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—HRAS—sarcoma	4.01e-05	0.000193	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—PLCG1—sarcoma	3.92e-05	0.000189	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—IL2—sarcoma	3.83e-05	0.000185	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—CCND1—sarcoma	3.73e-05	0.00018	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—JUN—sarcoma	3.73e-05	0.000179	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—CTNNB1—sarcoma	3.7e-05	0.000178	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—SRC—sarcoma	3.34e-05	0.000161	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—VEGFA—sarcoma	3.26e-05	0.000157	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—NRAS—sarcoma	3.22e-05	0.000155	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—MYC—sarcoma	3e-05	0.000144	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—EGFR—sarcoma	2.93e-05	0.000141	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—KRAS—sarcoma	2.77e-05	0.000133	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—TP53—sarcoma	2.46e-05	0.000118	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—HRAS—sarcoma	2.35e-05	0.000113	CbGpPWpGaD
